BRUKER CORPORATION

(BRKR)
  Report
Real-time Estimate Cboe BZX  -  05/16 12:14:59 pm EDT
59.43 USD   -1.30%
09:49aBruker Board Declares Quarterly Dividend of $0.05 Per Common Share, Payable June 17 to Shareholders as of June 1
MT
07:01aBruker Announces Quarterly Dividend
BU
05/10Bruker and TOFWERK Form Strategic Partnership in High-Speed, Ultra-Sensitive Solutions for Applied and Industrial Markets
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Bruker : Expands Proteomics Strategy with PreOmics

01/18/2022 | 04:22pm EDT
BeatBox by PreOmics for high throughput
tissue and cell homogenization

PreOmics Announces Closing of Series B Financing to Accelerate Research, Development and Commercialization of Proteomics Tools and Consumables

PreOmics Offers Unique Technologies, Advanced Automation Solutions and High-Performance Consumables for the Homogenization, Enrichment and Sample Preparation of Biopsy, Tissue, Cell Line and Plasma Samples in Unbiased, Deep Proteomics for Biopharma and Clinical Research

MUNICH, Germany - January 18, 2022 - PreOmics GmbH, a Martinsried, Germany-based developer of innovative automation and sample preparation tools and consumables for unbiased, deep proteomics analysis by mass spectrometry, has raised €13.5m in a Series B financing round provided by Bruker Corporation (Nasdaq: BRKR). PreOmics was founded in 2016 by Dr. Garwin Pichler and Dr. Nils A. Kulak as a spin-out company from the laboratory of leading proteomics researcher Professor Matthias Mann at the Max Planck Institute of Biochemistry in Martinsried.

PreOmics' innovative sample processing technologies for mass spectrometry-based protein analysis are complementary to Bruker's high-performance scientific instruments, as well as to proteomics mass spectrometry systems by other leading proteomics companies. Close collaboration synergies are expected to broaden the market opportunities for both PreOmics' BeatBox platform technologies and Bruker's timsTOF 4D proteomics platform with more complete, automated workflow solutions for academic and clinical researchers, for biomarker discovery and diagnostics companies, as well as for CRO and biopharmaceutical companies.

Dr. Garwin Pichler, Co-Founder and Managing Director of PreOmics, commented: "We are excited to increase R&D, marketing and sales investments, and are pleased to have Bruker as a collaborator and major investor. Bruker shares our vision for advanced proteomic discovery processes for everyone, and a commitment to accelerate PreOmics' growth. Our existing and future customers and partners will benefit from accelerated investments at PreOmics and from proteomics solution synergies to extend our product offerings and global presence."

Dr. Nils A. Kulak, Co-Founder and Managing Director of PreOmics, added: "We see a bright future for PreOmics' research, development and commercialization efforts, now accelerated by the Series B primary investments and Bruker as partner and

scientific collaborator. Our novel BeatBox technology is seamlessly compatible with PreOmics' proteomic sample preparation technologies and in combination with the timsTOF Pro provides end-to-end workflows for processing of large tissue biobanks. Furthermore, we aim to develop integrated and automated BeatBox-based workflow solutions for every experience level and throughput need, while providing highest performance levels for unbiased, deep and comprehensive proteomics research."

In conjunction with the Series B financing, several early investors in PreOmics, such as High-Tech Gründerfonds (HTGF) and Think.Health Ventures, as well as certain business angels, have successfully sold their PreOmics shares to Bruker in a parallel secondary transaction, and Bruker is now a majority investor in PreOmics. Financial details of the secondary transactions were not disclosed.

Dr. Bernd Goergen, Partner with HTGF, commented on the successful exit: "The fact that our time as a seed investor in Preomics has come to an end already after 5 years is a proof for the fantastic performance of both the management and the extremely innovative technology. Thank you, Garwin and Nils, for having us support a part of your journey. Joining forces with Bruker now paves

1

the way for setting gold standards in protein sample preparation and will make proteome analysis easier and more reliable than ever."

Dr. Michael Ruoff of Think.Health Ventures said: "Think.Health is grateful for having shared an important part of PreOmics' success story, which will continue also beyond our investment with the great support by Bruker. We appreciate Garwin and Nils as exceptional scientists and visionary entrepreneurs - a rare combination that we definitely need more of in Germany."

Dr. Frank H. Laukien, President and CEO of Bruker Corporation, stated: "We are very pleased to invest in PreOmics, a leading proteomics sample preparation, automation and consumables company, with this Series B primary financing. By also acquiring a majority investment in PreOmics, Bruker further expands its proteomics vision to include the unique PreOmics sample preparation technologies, as well as more comprehensive, automated, robust and reproducible workflows and consumables for translational, biomarker and biopharma proteomics research."

About PreOmics GmbH

PreOmics empowers our clients in life sciences to establish biological knowledge through efficient, reliable solutions and workflows that set the standard for protein analysis. Our team spirit, energy, and commitment empower us to be both creative and quality focused - A trusted partner with deeply rooted scientific experience. We envisage a future with revolutionary proteomic discovery processes open for everyone. Tools that reveal hidden causes of diseases, ensure sustainable nutrition, and provide diagnoses that enhance lives and society.

For more information, contact:

Dr. Garwin Pichler, Founder & Managing Director

PreOmics GmbH

Phone: +49 (0) 89 / 23 14 163 - 0

Email: info@preomics.com

Website: www.preomics.com

Address: Am Klopferspitz 19 | 82152 Planegg/Martinsried | Germany

About Think.Health Ventures

Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek for innovations and disruptive business models in digital healthcare, life sciences, pharmaceuticals and biotechnology. For more information please visit www.think-health.de.

About High-Tech Gründerfonds

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential,tech-driven start- ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 650 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF's focus is on high-techstart-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3.5 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds. HTGF has also successfully sold interests in more than 150 companies.

Investors in this public-private partnership include the Federal Ministry for Economic Affairs and Climate Action, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Bank,

2

Deutsche Post DHL, Dräger, 1+1 AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

www.htgf.de/en

Media Contact

High-Tech Gründerfonds Management GmbH

Stefanie Grüter, Head of Marketing & Communications

T.: +49 228 - 82300 - 188

s.grueter@htgf.de

Investor Contact

High-Tech Gründerfonds Management GmbH Dr. Bernd Goergen, Partner

T.: +49 228 - 82300 - 136 b.goergen@htgf.de

3

Disclaimer

Bruker Corporation published this content on 18 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2022 21:20:58 UTC.


ę Publicnow 2022
All news about BRUKER CORPORATION
09:49aBruker Board Declares Quarterly Dividend of $0.05 Per Common Share, Payable June 17 to ..
MT
07:01aBruker Announces Quarterly Dividend
BU
05/10Bruker and TOFWERK Form Strategic Partnership in High-Speed, Ultra-Sensitive Solutions ..
BU
05/09Bruker Launches Novel 7 Tesla and 9.4 Tesla Preclinical MRI Magnets
BU
05/09Bruker Launches Novel 7 Tesla and 9.4 Tesla Preclinical MRI Magnets
CI
05/06BRUKER CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
05/05SVB Leerink Adjusts Bruker's Price Target to $87 from $85, Keeps Outperform Rating
MT
05/05Bruker Corporation acquired unknown minority stake in Tofwerk AG for CHF 18 million.
CI
05/04TRANSCRIPT : Bruker Corporation, Q1 2022 Earnings Call, May 04, 2022
CI
05/04Bruker Corporation Revises Revenue Guidance for the Year 2022
CI
More news
Analyst Recommendations on BRUKER CORPORATION
More recommendations
Financials (USD)
Sales 2022 2 568 M - -
Net income 2022 300 M - -
Net Debt 2022 157 M - -
P/E ratio 2022 29,9x
Yield 2022 0,31%
Capitalization 8 987 M 8 987 M -
EV / Sales 2022 3,56x
EV / Sales 2023 3,30x
Nbr of Employees 7 765
Free-Float 57,8%
Chart BRUKER CORPORATION
Duration : Period :
Bruker Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRUKER CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 60,21 $
Average target price 75,63 $
Spread / Average Target 25,6%
EPS Revisions
Managers and Directors
Frank H. Laukien Chairman, President & Chief Executive Officer
Gerald N. Herman Chief Financial Officer & Executive Vice President
William Alderman Linton Lead Independent Director
Richard A. Packer Independent Director
Hermann Fritz Requardt Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BRUKER CORPORATION-28.24%8 987
THERMO FISHER SCIENTIFIC-18.86%211 945
DANAHER CORPORATION-24.26%178 394
INTUITIVE SURGICAL, INC.-37.74%80 295
SIEMENS HEALTHINEERS AG-17.38%63 485
EDWARDS LIFESCIENCES CORPORATION-24.70%60 652